Type of surgery by site, n (%)
|
Not performed
|
2 (5.1)
|
Primary tumour
|
3 (7.7)
|
| Left hemicolectomy |
1 (2.6) |
| Right hemicolectomy |
1 (2.6) |
Anterior resection of rectum
|
1 (2.6)
|
Metastases
|
37 (94.9)
|
| Bi-segmentectomy |
14 (35.9) |
| Segmentectomy |
7 (17.9) |
| Left hepatectomy |
5 (12.8) |
| Right hepatectomy |
2 (5.1) |
| Enlarged right hepatectomy |
2 (5.1) |
| Wedge resection |
1 (2.6) |
Other partial hepatic resections
|
6 (15.4)
|
Time from last bevacizumab, median (range), weeks
|
9 (6–15)
|
Time from last chemotherapy, median (range), weeks
|
6 (3–13)
|
Radiofrequency ablation associated, n (%)
|
8 (21.6)
|
Surgical outcome, n (%)
|
| R0 |
33 (84.6) |
| R1 |
2 (5.1) |
R2+ not operable
|
4 (10.3)
|
At least one surgery-related toxicity, n (%)
|
| No |
21 (56.8) |
Yes
|
16 (43.2)
|
Surgery-related toxicity, n (%)
|
| Biloma |
12 (32.4) |
| Pleural effusion |
3 (8.1) |
| Hepatic abscess |
1 (2.7) |
| Fistula |
1 (2.7) |
| Common bile duct injury |
1 (2.7) |
| Pancreatitis |
1 (2.7) |
| Wound dehiscence |
1 (2.7) |
